Lundbeck’s STARSHINE Fades As Idalopirdine Fails First Phase III Alzheimer’s Test

Lundbeck’s 5-HT6 antagonist idalopirdine failed its first Phase III test, but as Axovant awaits data from its Phase III study for a competing Alzheimer’s therapy, it’s still unclear whether the entire drug class is doomed to the same fate.

Hope for a new add-on treatment for Alzheimer’s disease symptoms faded on Sept. 22 as H. Lundbeck AS reported that neither dose of idalopirdine given in combination with donepezil met the primary or secondary endpoints in the Phase III STARSHINE clinical trial.

Valby, Denmark-based Lundbeck said idalopirdine “showed a weak efficacy profile,” raising questions about whether a competing 5-HT6 antagonist from Axovant Sciences Ltd. will achieve statistical significance in its Phase III trial, from which data are expected in the fourth quarter of 2017

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

In Brief: US FDA Delay Sends Biohaven Shares Down

16 May 2025

• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Multiple Launches Help Lilly’s Japan Growth

15 May 2025

• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Lundbeck Lifted By Leap In Migraine Therapy Sales

14 May 2025

• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

13 May 2025

• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

19 May 2025

• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.